rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Celularity Inc.

CELU · Nasdaq

Health CareBiotechnologyIn trend

CELU stood above a rising 150-day average in 6 of the last 52 weekly readings, including each of the last 6 weeks. It is 19.5% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
In trend
Weeks in an uptrend
6 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
38 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders38+2 on the quarter
New · exited6 · 4
Reported value$2.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
C V STARR & CO INCunchanged · filed 11 Aug 2026764,069$1.6M00.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026621,105$371K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026167,150$100K-23,926−12.5%
CITADEL ADVISORS LLCnew · filed 14 Aug 202699,054$59K+99,054
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202679,874$48K00.0%
BlackRock, Inc.reduced · filed 7 Aug 202676,359$46K-51,142−40.1%
STATE STREET CORPunchanged · filed 7 Aug 202657,830$35K00.0%
NORTHERN TRUST CORPunchanged · filed 13 Aug 202644,163$26K00.0%
Biltmore Family Office, LLCunchanged · filed 12 Aug 202635,000$21K00.0%
HB Wealth Management, LLCreduced · filed 29 Jul 202631,915$19K-8,500−21.0%
31 Mar 2024 – 30 Jun 2026
253238Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Daniele Wolf Barach Company insider10% owner · last 23 Sep 20260 · 0
Philip & Daniele Barach Family Trust Company insider10% owner · last 23 Sep 20260 · 0
Philip Alan Barach Company insiderDirector, 10% owner · last 23 Sep 20260 · 0
John R. Haines Company insiderSenior Exec Vice President · last 13 Apr 20260 · 0
Robert J. Hariri Company insiderChief Executive Officer · last 13 Apr 20265 · 0
Stephen Brigido Company insiderPres., Functional Regeneration · last 13 Apr 20260 · 0
Diane L. Parks Company insiderDirector · last 12 Jan 20260 · 0
Geoffrey Ling Company insiderDirector · last 12 Jan 20260 · 0
Peter Diamandis Company insiderDirector · last 12 Jan 20260 · 0
Vincent LeVien Company insiderDirector · last 12 Jan 20260 · 0
Kok Thay Lim Company insider10% owner · last 24 Jul 20250 · 0
David C. Beers Company insiderChief Financial Officer · last 13 Apr 20250 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202524.4%
Operating profit marginFY 2025 · to 31 Dec 2025-231%
Research spendFY 2025 · to 31 Dec 202556.6%
Share count trendFY 2025 · to 28 Apr 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.2M

Analyst forecasts

No analyst forecasts yet.